1542034-22-9

Upstream product

• 293751-03-8 1,2-di-O-acetyl-3-O-benzyl-4-C-methanesulfonyloxymethyl-5-O-methanesulfonyl-D-erythro-pentofuranose 
• 83255-86-1 3-bromo-4-aminopyrazolo<3,4-d>pyrimidine 
• 1542034-19-4 [(1R,3R,4R,7S)-3-(4-amino-3-bromo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-7-(benzyloxy)-2,5-dioxabicyclo[2.2.1]hept-1-yl]methyl benzoate 
• 1542034-16-1 [(1R,3R,4R,7S)-3-(4-amino-3-bromo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-7-(benzyloxy)-2,5-dioxabicyclo[2.2.1]hept-1-yl]methyl mesylate 
• 1542034-15-0 (2R,3R,4S)-2-(4-amino-3-bromo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-4-(benzyloxy)-5,5-bis[(mesyloxy)methyl]tetrahydrofuran-3-yl acetate 

Relevant academic research and scientific papers

Highly efficient synthesis of allopurinol locked nucleic acid monomer by C6 deamination of 8-aza-7-bromo-7-deazaadenine locked nucleic acid monomer

An allopurinol locked nucleic acid (LNA) monomer was prepared by a novel strategy through C6 deamination of the corresponding 8-aza-7-bromo-7- deazaadenine LNA monomer with aqueous sodium hydroxide. An 8-aza-7-deazaadenine LNA monomer was also synthesized by a modification of the new synthetic pathway. N-Glycosylation at the 8-position was prevented by steric hindrance from the 7-bromo atom in the starting material 8-aza-7-bromo-7-deazaadenine. In the final step of the synthesis, the bromine was removed together with a benzyl protecting group by catalytic reduction with ammonium formate to give the required LNA monomers. Georg Thieme Verlag Stuttgart New York.